Viatris (VTRS) News Today $13.13 +0.08 (+0.61%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Viatris Q3 Earnings TranscriptNovember 20 at 7:15 AM | marketbeat.comViatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript)November 15, 2024 | seekingalpha.comViatris Underperform Rating: Limited Growth Prospects and Conservative Capital Allocation StrategyNovember 9, 2024 | markets.businessinsider.comViatris Inc. (NASDAQ:VTRS) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comViatris price target raised to $12 from $11 at BarclaysNovember 9, 2024 | markets.businessinsider.comBargain Priced Viatris Reports Strong Q3 Earnings ResultsNovember 8, 2024 | seekingalpha.comViatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...November 8, 2024 | finance.yahoo.comViatris Inc. Reports Strong Q3 2024 PerformanceNovember 8, 2024 | markets.businessinsider.comViatris Inc. Q3 Profit Decreases, But Beats EstimatesNovember 7, 2024 | markets.businessinsider.comGeneric Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt PaydownNovember 7, 2024 | benzinga.comViatris Tops Analyst Estimates in Q3November 7, 2024 | fool.comViatris nears 11-month high after Q3 beatNovember 7, 2024 | msn.comViatris Inc. (VTRS) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comViatris Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 7, 2024 | seekingalpha.comXanax maker Viatris beats quarterly estimates on demand for new generic drugsNovember 7, 2024 | reuters.comViatris Q3 Earnings Preview: Focus on upcoming product launches and EBITDA growthNovember 6, 2024 | msn.comAre Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?November 6, 2024 | msn.comViatris Announces Third Quarter 2024 DividendNovember 5, 2024 | prnewswire.comViatris to Report Q3 Earnings: What's in the Cards?November 4, 2024 | msn.comViatris Named to Forbes' World's Top Companies for Women 2024 ListOctober 29, 2024 | prnewswire.comViatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare ConferenceOctober 29, 2024 | prnewswire.comIdorsia announces financial results for the first nine months of 2024October 29, 2024 | globenewswire.comEarnings Preview: What To Expect From Viatris' ReportOctober 27, 2024 | msn.comViatris: Promising Financial Outlook with Strategic Share Repurchase and Low Valuation PotentialOctober 16, 2024 | markets.businessinsider.comViatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and EuropeOctober 16, 2024 | prnewswire.comViatris Settles Lawsuit, Avoids Antitrust Charges, and Advances Effexor StudyOctober 16, 2024 | uk.finance.yahoo.comViatris Inc. (VTRS): A Strategic Shift in Healthcare InvestmentsOctober 13, 2024 | msn.comViatris Inc (VTRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic InnovationsOctober 9, 2024 | finance.yahoo.comViatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick FactsOctober 9, 2024 | markets.businessinsider.comViatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)October 9, 2024 | prnewswire.comIs Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20?October 8, 2024 | msn.comViatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a RowOctober 8, 2024 | prnewswire.comNovo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: reportOctober 7, 2024 | seekingalpha.comNovo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss DrugsOctober 7, 2024 | msn.comViatris Inc. (VTRS.VI)September 21, 2024 | sg.finance.yahoo.comVTRS Oct 2024 16.000 callSeptember 21, 2024 | ca.finance.yahoo.comVTRS Jan 2025 20.000 callSeptember 21, 2024 | ca.finance.yahoo.comViatris Announces the Pricing Terms of Maximum Tender OfferSeptember 18, 2024 | prnewswire.comViatris Announces Early Tender Results and Increase of Pending Maximum Tender OfferSeptember 17, 2024 | prnewswire.comDo Options Traders Know Something About Viatris (VTRS) Stock We Don't?September 16, 2024 | msn.comViatris to Report Third Quarter 2024 Financial Results on November 7, 2024September 16, 2024 | prnewswire.comViatris 2023 Sustainability Report: Advocating for PatientsSeptember 12, 2024 | finanznachrichten.deViatris Announces Expiration and Results of Any and All Cash Tender OffersSeptember 10, 2024 | prnewswire.comViatris Inc.: Viatris Announces the Pricing Terms of Pending Any and All Cash Tender OffersSeptember 10, 2024 | finanznachrichten.deViatris Announces the Pricing Terms of Pending Any and All Cash Tender OffersSeptember 10, 2024 | prnewswire.comViatris 2023 Sustainability Report: Breaking Down Systemic Barriers To Access Through Policy EngagementSeptember 9, 2024 | stockhouse.comViatris Announces Cash Tender Offers for Certain Outstanding NotesSeptember 4, 2024 | prnewswire.comViatris Q2 Earnings TranscriptAugust 29, 2024 | marketbeat.comViatris Inc. (VIA.F)August 27, 2024 | uk.finance.yahoo.comViatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual CongressAugust 23, 2024 | prnewswire.com Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. VTRS Media Mentions By Week VTRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTRS News Sentiment▼0.230.45▲Average Medical News Sentiment VTRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTRS Articles This Week▼23▲VTRS Articles Average Week Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News BioNTech News Teva Pharmaceutical Industries News BeiGene News Summit Therapeutics News Moderna News Genmab A/S News Dr. Reddy's Laboratories News Vaxcyte News Catalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTRS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTRS Stock Alerts